NDRG2 and neoplasm: In addition, NDRG2 promotor methylation was found to be tumor-specific and associated with shorter survival in patients who survived less than 24 months (4.6 months, methylated; 7.8 months, non-methylated), but was not associated with overall survival (n = 137) [83].